Jie-Yun Xia

B-cell maturation antigen-targeted CAR T cell as a salvage therapy for progressive multiple myeloma after anti-G proteincoupled receptor, class C group 5 member D CAR T-cell therapy.

Repeat infusion of chimeric antigen receptor (CAR) T-cell is effective for patients with refractory or relapsed multiple myeloma (RRMM) after failing a prior CAR Tcell therapy. It is unknown whether B-cell maturation antigen (BCMA) CAR T-cell is effective for patients with RRMM after anti-G protein-coupled receptor, cl...